Imagine a world where doctors are able to target and remove pathogens, such as harmful cells, bacteria, toxins, and inflammatory cytokines, directly from a patient’s bloodstream. That is MediSieve’s vision for the future of healthcare, which can be achieved through the process of Magnetic Haemofiltration.
MediSieve’s first product targets IL-6 cytokine to treat various hyperinflammation condition like Sepsis, COVID-19, and Cytokine Release Syndrome.
MediSieve plans to use a combination of different magnetic beads to target the various pathogens and cytokines that lead to the symptoms of Sepsis.
The device rapidly reduces the parasitaemia of severe Malaria patients who have been hospitalised and prescribed IV drug treatment.
The MediSieve System purifies blood by targeting harmful substances with magnetic beads
London, hosted by BIA
BioInvestor Forum (New York) - 10th - 11th February 2020
Radboud University Medical Center will perform the first trial of the Novel Magnetic Haemoflitratio...
MediSieve, a biotech company that has developed an innovative blood filtration device, receives ...